Preferences of people living with HIV for features of tuberculosis preventive treatment regimens in Uganda: a discrete choice experiment
Journal of the International AIDS Society · 2024
DOI: 10.1002/jia2.26390 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the International AIDS Society, 2024. Verfasst von Hélène E Aschmann und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco, California, USA. Hauptthemen laut MEDLINE: HIV Infections, Tuberculosis, Antitubercular Agents, Patient Preference. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Early Postdoc.Mobility, National Heart, Lung and Blood Institute, NIAID NIH HHS.
Abstract (Originalsprache)
Introduction
Tuberculosis (TB) preventive treatment (TPT) is recommended for people living with HIV (PLHIV) in high TB burden settings. While 6 months of daily isoniazid remains widely used, shorter regimens are now available. However, little is known about preferences of PLHIV for key features of TPT regimens.
Methods
From July to November 2022, we conducted a discrete choice experiment among adult PLHIV engaged in care at an urban HIV clinic in Kampala, Uganda. Participants chose between two hypothetical TPT regimens with five different features (pills per dose, frequency, duration, need for adjusted antiretroviral therapy [ART] dosage and side effects), organized across nine random choice tasks. We analysed preferences using hierarchical Bayesian estimation, latent class analysis and willingness‐to‐trade simulations.
Results
Of 400 PLHIV, 392 (median age 44, 72% female, 91% TPT‐experienced) had high‐quality choice task responses. Pills per dose was the most important attribute (relative importance 32.4%, 95% confidence interval [CI] 31.6–33.2), followed by frequency (20.5% [95% CI 19.7–21.3]), duration (19.5% [95% CI 18.6–20.5]) and need for ART dosage adjustment (18.2% [95% CI 17.2–19.2]). Latent class analysis identified three preference groups: one prioritized less frequent, weekly dosing ( N = 222; 57%); another was averse to ART dosage adjustment ( N = 107; 27%); and the last prioritized short regimens with fewer side effects ( N = 63; 16%). All groups highly valued fewer pills per dose. Overall, participants were willing to accept a regimen of 2.8 months’ additional duration [95% CI: 2.4–3.2] to reduce pills per dose from five to one, 3.6 [95% CI 2.4–4.8] months for weekly rather than daily dosing and 2.2 [95% CI 1.3–3.0] months to avoid ART dosage adjustment.
Conclusions
To align with preferences of PLHIV in Uganda, decision‐makers should prioritize the development and implementation of TPT regimens with fewer pills, less frequent dosing and no need for ART dosage adjustment, rather than focus primarily on duration of treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco, California, USA.
- Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.
- Center for Tuberculosis, University of California San Francisco, San Francisco, California, USA.
- Infectious Diseases Research Collaboration, Kampala, Uganda.
- Uganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda.
- Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
ORCID-Profile: Allan Musinguzi, David W Dowdy, Fred C Semitala, Andrew D Kerkhoff
Förderung
- Early Postdoc.Mobility
- National Heart, Lung and Blood Institute
- NIAID NIH HHS
- TB Research Advancement Center
- NIH HHS
- Postdoc.Mobility
- UCSF Center for Tuberculosis
- NHLBI NIH HHS
Zitieren
APA
Aschmann, H. E., Musinguzi, A., Kadota, J. L., Namale, C., Kakeeto, J., Nakimuli, J., Akello, L., Welishe, F., Nakitende, A., Berger, C., Dowdy, D. W., Cattamanchi, A., Semitala, F. C., & Kerkhoff, A. D. (2024). Preferences of people living with HIV for features of tuberculosis preventive treatment regimens in Uganda: a discrete choice experiment. Journal of the International AIDS Society. https://doi.org/10.1002/jia2.26390
Vancouver
Aschmann HE, Musinguzi A, Kadota JL, Namale C, Kakeeto J, Nakimuli J, et al. Preferences of people living with HIV for features of tuberculosis preventive treatment regimens in Uganda: a discrete choice experiment. Journal of the International AIDS Society. 2024. doi:10.1002/jia2.26390
BibTeX
@article{Aschmann2024,
author = {Aschmann, Hélène E and Musinguzi, Allan and Kadota, Jillian L and Namale, Catherine and Kakeeto, Juliet and Nakimuli, Jane and Akello, Lydia and Welishe, Fred and Nakitende, Anne and Berger, Christopher and Dowdy, David W and Cattamanchi, Adithya and Semitala, Fred C and Kerkhoff, Andrew D},
title = {Preferences of people living with HIV for features of tuberculosis preventive treatment regimens in Uganda: a discrete choice experiment},
journal = {Journal of the International AIDS Society},
year = {2024},
doi = {10.1002/jia2.26390}
}
EUVIMED